CytomX Therapeutics, Inc. (CTMX) SEC filings

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30

$2.04+0.00 (0.00%)

Close on Nov 13, 2026Market cap $444.52MP/E –Yield –

SEC filings

40 of CytomX Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jul 24, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 22, 2026	SEC EDGAR
Current report	8-K	May 29, 2026	Jun 3, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 17, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 19, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 16, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 16, 2026	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 13, 2025	SEC EDGAR
Current report	8-K	May 27, 2025	May 28, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 12, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 12, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Mar 6, 2025	Mar 6, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 6, 2025	SEC EDGAR
Current report	8-K	Feb 24, 2025	Feb 26, 2025	SEC EDGAR
Current report	8-K	Jan 30, 2025	Feb 3, 2025	SEC EDGAR
Current report	8-K	Jan 6, 2025	Jan 6, 2025	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jun 12, 2024	Jun 17, 2024	SEC EDGAR
Current report	8-K	May 15, 2024	May 17, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Proxy statement	DEF 14A	May 15, 2024	Apr 4, 2024	SEC EDGAR
Current report	8-K	Mar 20, 2024	Mar 22, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in CytomX Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CTMX.

Compare: CTMX vs JANX · CTMX vs PYXS · CTMX vs CBIO · CTMX vs PRLD · CTMX vs ADAG

Revenue growth-87.7% · median 176.6%

Operating margin-676.5% · median -599.3%

Net margin-609.0% · median -428.7%

Company	Revenue	Growth
JANX	$23.29M	+132.9%
PRLD	$22.42M	+220.3%
CBIO	$15.00M	–
CTMX	$14.03M	-87.7%
PYXS	–	–
ADAG	–	–

Company

Next earnings (est.): Mar 15, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 69
Held by institutions: 97.9%
Auditor: Ernst & Young LLP
SEC CIK: 1501989

Advertisement
300 × 250

See a number that looks wrong?